Plain-English translation of NCT05644431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at how standard chemotherapy affects the immune system's response to stomach cancer. Researchers will collect tissue samples from your tumor before and after chemotherapy, along with regular blood samples, to understand how the treatment changes immune cells around the cancer. This information may help doctors develop better treatments in the future.
Doctors know that chemotherapy can work in different ways—not just by killing cancer cells directly, but also by helping your immune system fight the cancer better. This study aims to understand exactly how this happens, which could lead to better treatment strategies for people with stomach cancer.
You likely qualify if…
You likely don't qualify if…
You would receive your standard chemotherapy as planned, and researchers would collect extra tissue and blood samples at specific timepoints—before chemotherapy starts, after chemotherapy ends, and during follow-up visits. These samples help scientists track how your immune system changes during treatment. The study is non-therapeutic, meaning its main purpose is research rather than direct treatment benefit, though your standard cancer care continues normally.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France
Sponsor
Centre Leon Berard
Enrollment target
~50 participants
Started
July 2023
Primary completion
January 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clélia COUTZAC, MD
Centre Leon Berard
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.